Stockscreener 앱 받기
31.27
3.78%
1.14
시장 영업 전:
31.02
-0.25
-0.80%
Alkermes Plc 주식(ALKS)의 최신 뉴스
Drug Abuse Treatment Market Grows Amid Rising Substance Abuse - openPR.com
Cantor Fitzgerald maintains $43 target on Alkermes stock By Investing.com - Investing.com Nigeria
Controlled Release Drug Delivery Market is in trends - openPR.com
Alkermes plc Earnings Call Highlights Growth and R&D Progress - MSN
When the Price of (ALKS) Talks, People Listen - news.stocktradersdaily.com
Alkermes plc (ALKS): Among Billionaire Jim Simons’ RenTech’s Small-Cap Stock Picks with Huge Upside Potential - Insider Monkey
Alkermes plc (NASDAQ:ALKS) Q1 2025 Earnings Call Transcript - Insider Monkey
Alkermes has near-term catalyst with narcolepsy data, says H.C. Wainwright - TipRanks
BlackRock, Inc. Reduces Stake in Alkermes PLC: A Detailed Analysis - GuruFocus
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm - ACCESS Newswire
RBC Capital Raises Price Target for Alkermes (ALKS) to $40 | ALKS Stock News - GuruFocus
Alkermes' Q1 Earnings and Revenues Fall Short of Estimates - Nasdaq
Alkermes (ALKS) Reaffirms 2025 Financial Outlook and Awaits Key Trial Results | ALKS Stock News - GuruFocus
Alkermes (ALKS) Price Target Raised to $41 by Baird Analyst | AL - GuruFocus
Alkermes (ALKS) Price Target Raised to $41 by Baird Analyst | ALKS Stock News - GuruFocus
Baird Increases Price Target for Alkermes (ALKS) on Promising Ou - GuruFocus
Baird Increases Price Target for Alkermes (ALKS) on Promising Outlook | ALKS Stock News - GuruFocus
RBC Raises Price Target on Alkermes to $40 From $39, Keeps Sector Perform Rating - marketscreener.com
Alkermes PLC (ALKS) Q1 2025 Earnings Call Highlights: Strong Proprietary Product Growth and ... - Yahoo
Alkermes PLC (ALKS) Q1 2025 Earnings Call Highlights: Strong Pro - GuruFocus
Alkermes: Q1 Earnings Snapshot - MySA
Alkermes plc Reports Q1 2025 Financial Results - TipRanks
Alkermes Plc earnings missed by $0.18, revenue fell short of estimates - Investing.com South Africa
Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible (NASDAQ:ALKS) - Seeking Alpha
Chondrosarcoma Market: Epidemiology, Therapies, Companies, - openPR.com
Alkermes to Report First Quarter Financial Results on May 1, 2025 - PR Newswire UK
Alkermes Q1 2025 Earnings Call Transcript - MarketBeat
Here's What Key Metrics Tell Us About Alkermes (ALKS) Q1 Earnings - Yahoo Finance
Alkermes Q1 Earnings, Revenue Decline - marketscreener.com
Alkermes Plc reports results for the quarter ended March 31Earnings Summary - TradingView
Alkermes PLC Q1 2025 Earnings: EPS of $0.13 Beats Estimate, Reve - GuruFocus
Alkermes (ALKS) Misses Q1 Earnings and Revenue Estimates - Yahoo Finance
Alkermes (ALKS) Exceeds Q1 Revenue Expectations and Advances Ore - GuruFocus
Alkermes (ALKS) Exceeds Q1 Revenue Expectations and Advances Orexin 2 Program | ALKS Stock News - GuruFocus
Earnings Flash (ALKS) Alkermes Posts Q1 EPS of $0.13, vs. FactSet Est of $0.05 - marketscreener.com
Earnings Flash (ALKS) ALKERMES PLC Reports Q1 Revenue $306.5M, vs. FactSet Est of $302.9M - marketscreener.com
Alkermes plc Reports First Quarter 2025 Financial Results - PR Newswire UK
Do Options Traders Know Something About Alkermes Stock We Don't? - Nasdaq
Drug Detoxification Market Is Booming Worldwide 2025-2032 | - openPR.com
New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD) - PR Newswire
How to Take Advantage of moves in (ALKS) - news.stocktradersdaily.com
UBS Adjusts Alkermes (ALKS) Price Target Amid Softer Q1 Guidance - GuruFocus
Beyond The Numbers: 6 Analysts Discuss Alkermes Stock - Benzinga
UBS Adjusts Alkermes Public Price Target to $33 From $38, Maintains Neutral Rating - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline - Yahoo Finance
2.72%
2.17%
자본화:
|
볼륨(24시간):